BioTelemetry (NASDAQ:BEAT) released its earnings results on Thursday. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.19, MarketWatch Earnings reports. The company had revenue of $99.11 million for the quarter, compared to analyst estimates of $85.93 million. BioTelemetry had a net margin of 4.42% and a return on equity of 17.87%.

NASDAQ:BEAT opened at $42.56 on Friday. The company has a quick ratio of 4.19, a current ratio of 4.34 and a debt-to-equity ratio of 0.60. The company has a market cap of $1.45 billion, a P/E ratio of 81.85, a P/E/G ratio of 2.85 and a beta of 1.30. BioTelemetry has a fifty-two week low of $27.35 and a fifty-two week high of $55.85. The firm’s 50 day moving average is $43.53 and its two-hundred day moving average is $44.90.

A number of equities analysts have recently weighed in on BEAT shares. Zacks Investment Research raised shares of BioTelemetry from a “sell” rating to a “hold” rating in a research report on Tuesday, July 7th. BidaskClub lowered BioTelemetry from a “buy” rating to a “hold” rating in a research note on Friday, June 12th. Finally, SunTrust Banks restated a “buy” rating and set a $58.00 price objective on shares of BioTelemetry in a report on Wednesday, July 8th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.00.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Further Reading: What causes a recession?

Earnings History for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with's FREE daily email newsletter.